[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastroesophageal-reflux-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastroesophageal-reflux-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,44,73,103,127,151,181,213,241,265,293,315,343,361,383,405],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100643870","mindfulness-intervention-for-emotional-distress-mied-in-patients-with-gerd-100643870",false,"NCT07667894","Mindfulness Intervention for Emotional Distress (MIED) in Patients With GERD","Effects of an Online Mindfulness-Based Emotion Intervention on Symptoms and Emotional Distress in Patients With Gastroesophageal Reflux Disease: A Multicenter Randomized Waitlist-Controlled Trial","Inclusion Criteria\n\nParticipants must meet all of the following criteria:\n\n1. Aged 18 to 65 years.\n2. GERD-Q score of 8 or higher.\n3. Willingness to maintain a relatively stable usual treatment regimen during the study unless medically indicated changes are required.\n4. Ability to use a smartphone, computer, or tablet to participate in the online program and complete online questionnaires.\n5. Willingness to comply with course training and follow-up assessments.\n6. Ability to understand the study and provide written or electronic informed consent.\n\nExclusion Criteria\n\nParticipants meeting any of the following criteria will be excluded:\n\n1. Alarm symptoms or high suspicion of serious organic disease, including but not limited to progressive dysphagia, hematemesis, melena, unexplained weight loss, anemia, recurrent vomiting, or persistent chest pain without exclusion of cardiovascular risk.\n2. Current or previous severe esophageal organic disease or gastrointestinal malignancy.\n3. History of anti-reflux surgery, partial gastrectomy, or other upper gastrointestinal surgery that may substantially affect reflux symptom assessment.\n4. GERD-Q score greater than 15, or symptoms judged by the study physician to be extremely severe and requiring priority medical evaluation or intensified treatment.\n5. Current uncontrolled severe mental disorder, such as schizophrenia, manic episode of bipolar disorder, acute severe depressive episode, or severe substance use disorder.\n6. Current suicide risk, operationalized as a score greater than 1 on item 9 of the PHQ-9.\n7. Previous systematic participation in MIED, mindfulness-based stress reduction, mindfulness-based cognitive therapy, or another structured mindfulness program.","ALL","18 Years","65 Years",{"count":20,"type":21},500,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this multicenter randomized waitlist-controlled clinical trial is to evaluate whether an online Mindfulness-Based Intervention for Emotional Distress (MIED) can reduce emotional distress and reflux-related symptoms in adults with gastroesophageal reflux disease (GERD). GERD is a common chronic gastrointestinal condition that is frequently accompanied by anxiety, depressive symptoms, stress, and impaired quality of life.\n\nThe main questions this study aims to answer are:\n\nCan online MIED reduce emotional distress in patients with GERD?\n\nCan online MIED reduce reflux-related symptoms and improve reflux-related quality of life?\n\nAre changes in psychological processes, such as distress tolerance, cognitive flexibility, experiential avoidance, emotional behaviors, and life engagement, associated with improvements in emotional distress and reflux symptoms?\n\nResearchers will compare participants receiving online MIED with participants in a waitlist control group receiving usual medical care and health management to determine whether online MIED leads to greater improvement over time.\n\nParticipants will:\n\ncomplete screening and baseline assessments;\n\nbe randomly assigned to either the online MIED intervention group or the waitlist control group;\n\nif assigned to the intervention group, complete an 8-week online MIED program with one session per week;\n\ncontinue necessary usual medical care during the study, while keeping medication use stable when possible;\n\ncomplete online questionnaires at baseline, during the intervention, after the intervention, and at 3, 6, 12, and 24 months after the intervention;\n\nreport information on reflux symptoms, emotional distress, quality of life, sleep, stress, resilience, life satisfaction, healthcare use, intervention adherence, and adverse events.",[27,28],"Gastroesophageal Reflux Disease","Emotional Distress",[28,27,30],"Mindfulness Intervention for Emotional Distress","NOT_YET_RECRUITING","2026-06-19",{"date":34,"type":35},"2026-06-25","ACTUAL",{"date":37,"type":21},"2026-07-01",{"date":39,"type":21},"2028-05-15",{"name":41,"class":42},"Xinghua Liu","OTHER",15,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":4},"100421147","reflux-disease-after-gastric-bypass-versus-sleeve-gastrectomy-in-morbid-obese-patients-an-italian-study-100421147","NCT04763993","Reflux Disease After Gastric Bypass Versus Sleeve Gastrectomy in Morbid Obese Patients: an Italian Study","Reflux Disease After Gastric Bypass Versus Sleeve Gastrectomy in Morbid Obese Patients: an Italian Monocentric Randomized Clinical Study (ReBvSS)","ReBvSS","Inclusion Criteria:\n\n* Acceptance of randomization to surgery;\n* Participant is willing and able to give informed consent for participation in the trial;\n* Written informed consent;\n* Compliance to follow-up;\n* Male and female;\n* ≥18 and ≤70 years old;\n* BMI ≥ 35 with obesity-related comorbidities;\n* BMI ≥ 40 with or without obesity-related comorbidities;\n* GERDQ score ≥ 3 points;\n* Use of proton pump inhibitor;\n* Mild and Moderate GERD (DMS ≥14.72 ≤100)\n* Incompetence of the Esophagogastric junction\n* Los Angeles grade A, B, C, D esophagitis.\n\nExclusion criteria\n\n* Medical or psychiatric conditions that compromises the patient's ability to give informed consent or comply with the study protocol;\n* Barrett's esophagus (BE);\n* Spastic motor disorders and esophageal hypomotility;\n* Peptic strictures;\n* Absence of GERD (DMS\\\u003C14.72);\n* Severe GERD (DMS\\>100);\n* Hiatal hernia \\> 5 cm;\n* Previous bariatric surgery or major general surgery;\n* Type 2 diabetes (T2D) for more than \\> 5 years;\n* Necessity to explore stomach, the duodenum or the biliary tract;\n* Refuse of randomization;\n* Personal reasons.","70 Years",{"count":54,"type":21},128,[24],"The study aims to clarify if GERD, defined by results of 24 hours potential of hydrogen (pH) monitoring and abnormal DeMeester Score (DMS), in obese patients could worsen after Sleeve Gastrectomy (SG) more than after RYGBP. To demonstrate this hypothesis, the investigators will study the obese population suspected for GERD with 24 hours monitoring and High-Resolution Esophageal Manometry (HRM). DMS is calculated pre-operatively and, once GERD is confirmed, the patients are enrolled for randomization to SG or RYGBP. The suspicion of GERD is investigated with the GERDQ score and EGDS, that all obese patients have pre-operatory.",[27,58],"Obesity",[27,58,60,61,62,63],"Sleeve gastrectomy","Gastric bypass","DeMeester score","pH-monitoring","2026-04-13",{"date":66,"type":35},"2026-04-16",{"date":68,"type":21},"2026-05-01",{"date":70,"type":21},"2030-05-01",{"name":72,"class":42},"Niguarda Hospital",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100185996","phase-3-domperidone-in-treating-patients-with-gastrointestinal-disorders-100185996","NCT01696734","Domperidone in Treating Patients With Gastrointestinal Disorders","Treatment Protocol for the Compassionate Use of Domperidone","Inclusion Criteria:\n\n* Patients with GI disorders who have failed standard therapy\n* Symptoms or manifestations of: a) gastroparesis; b) refractory gastroesophageal reflux disease (GERD) including persistent esophagitis, refractory heartburn, reflux-related laryngitis, and respiratory symptoms; or c) severe dyspepsia\n* Completion of a comprehensive evaluation, including clinical history and physical examination, to eliminate other causes of their symptoms\n* Patient has signed the informed consent document agreeing to the use of the study drug, domperidone\n* White blood cell (WBC) with differential greater than 3,000\u002Fml\n* Alkaline phosphatase less than 1.5 x upper limit of normal\n* Alanine aminotransferase (ALT) less than 2 x upper limit of normal\n* Aspartate aminotransferase (AST) less than 2 x upper limit of normal\n* Bilirubin less than or equal to 2 x upper limit of normal\n* Blood urea nitrogen (BUN) less than 2 x upper limit of normal\n* Creatinine less than 1.5 x upper limit of normal\n* Stable hemoglobin greater than or equal to 8.0 g\u002Fdl\n* Potassium between range of 3.0 to 5.5\n* Magnesium level between 1.6-2.6 mg\n\nExclusion Criteria:\n\n* Patients with the following cardiac diagnoses: ventricular tachycardia or fibrillation; Torsade des Pointes; clinically significant bradycardia; sinus node dysfunction; heart block; prolonged QTc interval (QTc \\> 450 milliseconds for males, QTc \\> 470 milliseconds for females); prior specific cardiovascular conditions of clinically significant valvular heart disease requiring medication, ischemic, or pulmonary heart disease; cardiomyopathy; history of heart failure\n* Patients who are receiving antiarrhythmic medications with action on repolarization times (with prolongation of the QTc interval such as amiodarone, disopyramide, dofetilide, flecainide, ibutilide, quinidine, sotalol, dronedarone etc.)\n* Patients who are receiving monoamine oxidase (MAO) inhibitors\n* Patients with a history of or active liver failure\n* Clinically significant electrolyte disorders including sodium \\\u003C 130 or \\> 145 and\u002For potassium \\\u003C 3.0 or \\> 5.5 and\u002For magnesium \\\u003C 1.6 or \\> 2.6\n* GI hemorrhage or obstruction experienced within the previous 6 weeks\n* Presence of a prolactinoma (prolactin-releasing pituitary tumor)\n* Pregnant or breast-feeding female (women of childbearing potential \\[WOCBP\\], defined as not post-menopausal for 12 months or without previous surgical sterilization, must have a negative urine pregnancy test within 30 days of the first administration of domperidone and must either commit to continued abstinence from heterosexual intercourse or use an effective method of birth control during the course of the study)\n* Known allergy to domperidone","16 Years",{"count":82,"type":21},200,[84],"PHASE3","This phase III trial studies how well domperidone works in treating patients with gastrointestinal disorders. Domperidone may help control chronic gastrointestinal disorders and their symptoms, such as pain, bloating, and nausea and vomiting, by stimulating contraction of the stomach to increase its ability to empty itself of food.",[87,88,89,27,90,91,92],"Digestive System Disorder","Dyspepsia","Esophagitis","Gastroparesis","Heartburn","Nausea and Vomiting","RECRUITING","2026-04-10",{"date":64,"type":35},{"date":97,"type":35},"2012-10-23",{"date":99,"type":21},"2027-10-31",{"name":101,"class":42},"M.D. Anderson Cancer Center",1,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":126},"100576319","mechanistic-and-clinical-outcomes-of-a-surgical-innovation-aimed-at-minimizing-gerd-associated-with-vsg-innovate-vsg-100576319","NCT06783751","Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With VSG (INNOVATE-VSG)","Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With Vertical Sleeve Gastrectomy (INNOVATE-VSG)","INNOVATE-VSG","Inclusion Criteria:\n\n1. Male and female subjects aged 18-65 years\n2. Body mass index (BMI) 35-55 kg\u002Fm2\n3. Must meet the BMI criteria before and after 6 months of nonsurgical weight management\n4. Presence of GERD defined for this trial as acid exposure time (AET) of 4.9% or above as assessed with the Bravo pH test.\n5. Have health insurance which pays for the costs of bariatric surgery and standard medical care before and after surgery\n6. Women of childbearing potential must be using appropriate contraception to avoid pregnancy throughout the study, and must have a negative pregnancy test at study entry and prior to surgery\n7. Must be able to provide written informed consent\n\nExclusion Criteria:\n\n1. Hiatal hernia \\>2cm (defined as maximum axial height from end of the esophagus to diaphragm by any study including upper endoscopy esophagram and or at the time of surgery)\n2. Evidence of clinically significant major esophageal motility disorder as determined by the site primary investigator\n3. Severe gastroparesis\n4. Previous bariatric or anti-reflux procedure\n5. Barrett's esophagus\n6. Subjects requiring mesh treatment at time of procedure\n7. Severe heart (e.g., severe heart failure, unstable coronary artery disease), or end-stage lung disease as determined by the site primary investigator\n8. Subjects with pacemakers, implantable defibrillators, neurostimulators\n9. Portal hypertension or cirrhosis\n10. Chronic pancreatitis\n11. Active cancer treatment\n12. Inability to tolerate general anesthesia\n13. Uncontrollable coagulopathy\n14. Significant and uncontrolled inflammatory bowel disease\n15. Severe and\u002For uncontrolled psychiatric disorder (including psychosis, bipolar disorder) as determined during standard pre-surgery psychiatric screening at the site.\n16. Suicidal ideation or unstable\u002Funtreated major depressive disorder within the past year\n17. Alcohol or substance use disorder within the past year.\n18. Pregnant or breastfeeding or planning pregnancy in the coming 24 months\n19. Diminished intellectual capacity to consent or follow pre- and post-surgery instructions\n20. History of, or any current health condition that, in the opinion of the PI, would make the subject ineligible for sleeve gastrectomy, or put the subject at risk by participation in the study.",{"count":112,"type":21},44,[24],"This is a two-site randomized clinical trial aiming to test whether a modified investigational bariatric surgical procedure can improve gastroesophageal reflux disease (GERD) after sleeve gastrectomy.",[58,116,117,27],"Bariatric Surgery","Sleeve Gastrectomy","2026-04-08",{"date":64,"type":35},{"date":121,"type":35},"2025-03-21",{"date":123,"type":21},"2027-07-31",{"name":125,"class":42},"University of California, Irvine",2,{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":102},"100478806","proximal-gastrectomy-anterior-anastomosis-with-pyloroplasty-versus-esophagogastric-anastomosis-for-gastric-cancer-100478806","NCT05514769","Proximal Gastrectomy Anterior Anastomosis With Pyloroplasty Versus Esophagogastric Anastomosis for Gastric Cancer","Inclusion Criteria:\n\n1. Histologically confirmed adenocarcinoma of the stomach, T1-T4 stages.\n2. Eastern Cooperative Oncology Group performance status of 0 or 1.\n3. Adequate organ function.\n\nExclusion Criteria:\n\n1. Patients had distant metastasis.\n2. oesophageal invasion of more than 3 cm.\n3. Borrmann type 4 or large (more than 8 cm) type 3 carcinoma.\n4. Previous chemotherapy or radiation therapy for any other malignancies.","85 Years",{"count":135,"type":21},60,[24],"This research is designed to compare proximal gastrectomy anterior anastomosis with pyloroplasty with esophagogastric anastomosis for gastric cancer. Gastroesophageal reflux disease, postoperative quality of life, short term outcomes, and long term outcomes will be compared.",[139,140,27],"Proximal Gastric Adenocarcinoma","Gastric Cancer","2026-03-29",{"date":143,"type":35},"2026-03-31",{"date":145,"type":35},"2021-01-01",{"date":147,"type":21},"2027-12-31",{"name":149,"class":150},"Nanchong Central Hospital","OTHER_GOV",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":160,"briefSummary":162,"conditions":163,"keywords":165,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":102},"100570196","phase-2-oral-fosamprenavir--sodium-alginate-for-gerd-100570196","NCT06704100","Oral Fosamprenavir + Sodium Alginate for GERD","A Phase 2, Randomized, Double-blind, Placebo-controlled Trial of Fosamprenavir-Sodium Alginate Administered Orally for 8 Weeks to Patients With Proton Pump Inhibitor Refractory Gastroesophageal Reflux Disease","Inclusion Criteria:\n\n1. Patient aged 18-65 selected as candidate for anti-reflux surgery by study providers.\n2. Patient has received, and continued having GERD symptoms during, standard-labeled dose, daily, PPI therapy for a minimum of 8 weeks before the Screening Visit.\n3. Patient has a diagnosis of GERD with endoscopy and\u002For pH-metry test within the past two years demonstrating 1 or more of the following:\n\n   1. Erosive esophagitis (Grade A or greater based on the Los Angeles classification of esophagitis; Appendix 3)\n   2. Evidence of pathological acid reflux (pH \\\u003C 4 for ≥ 4-6% off therapy or ≥ 1-4% on therapy) during a 24-hour time interval of pH testing\n4. Patient reports heartburn severity (HS, Item #1 on mRESQ-eD) ≥ 3 (moderate) on at least 2 days and has an average HS of ≥ 2 (mild) during the last 7 days of the Pretreatment Period before Randomization.\n\nExclusion Criteria:\n\n1. Patient is suspected of having, functional upper gastrointestinal disorders such as functional dyspepsia or functional heartburn diagnosed by the Rome IV criteria; Appendix 4.\n2. Patient has endoscopically confirmed eosinophilic esophagitis (EE).","64 Years",{"count":135,"type":21},[161],"PHASE2","The goal of this clinical trial is to learn if study drug Fosamprenavir-Sodium Alginate (FOS-SA) administered orally improves symptoms for Proton Pump Inhibitor (PPI)-refractory Gastro Esophageal Reflux Disease (GERD).\n\nThe main questions it aims to answer are:\n\n1. Does FOS-SA significantly improve heartburn severity over the 8-week treatment period\n2. Does FOS-SA significantly improve regurgitation frequency over the 8-week treatment period\n3. Does FOS-SA significantly improve symptoms of persistent GERD over the 8-week treatment period\n\nResearchers will compare FOS-SA to a placebo (a look-alike substance that contains no active drug) to see if FOS-SA works to treat PPI-refractory GERD.\n\nParticipants will:\n\n1. Take FOS-SA or placebo every day BID (twice a day) for 8 weeks\n2. Visit the Adult Translational Research Unit (ATRU) seven times for consenting, screening, and checkups and tests\n3. Keep a daily diary of their symptoms of persistent GERD",[164,27],"Refractory Gastroesophageal Reflux Disease",[166,167,168,169,170,171],"PPI-refractory GERD","Proton pump inhibitor refractory gastroesophageal reflux disease","Fosamprenavir","Sodium Alginate","Fosamprenavir-Sodium Alginate","FOS-SA","2025-10-02",{"date":174,"type":35},"2025-10-06",{"date":176,"type":21},"2026-03-01",{"date":178,"type":21},"2028-06-01",{"name":180,"class":42},"Medical College of Wisconsin",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":22,"phases":190,"briefSummary":191,"conditions":192,"keywords":198,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":211,"locationsCount":102},"100382135","real-life-study-of-changes-of-gastroesophageal-reflux-disease-manifestations-due-to-behavioural-and-diet-adherence-100382135","NCT04255693","Real-life Study of Changes of Gastroesophageal Reflux Disease Manifestations Due to Behavioural and Diet Adherence","Inclusion Criteria:\n\n* willingness to participate (based on the signed informed consent form);\n* presence of gastroesophageal reflux disease, based on the following: a) typical symptoms, like heartburn and\u002For regurgitation (for primary selection, symptoms should be present at least weekly, be actual for at least 3 months prior to the enrolment, and the patient should report the history of symptoms which lasts for at least 6 months); b) previous response to the intake of proton pump inhibitors; c) data of 24-hours oesophageal pH-impedance monitoring with detected pathological gastroesophageal reflux according to the Lyon consensus definitions;\n\nExclusion Criteria:\n\n* pregnant or breast-feeding females;\n* abdominal or chest surgery (except appendectomy or cholecystectomy in case they are not followed by adhesive disease of the abdominal organs);\n* constant use of non-steroidal anti-inflammatory agents (NSAIDs), sporadic use of NSAIDs will be allowed in case the course of treatment was discontinued at least 2 weeks prior to the enrolment, in case that constant use of NSAIDs happen to be necessary after the enrolment, the patients may continue in the study but doses, frequency and duration of treatment should be carefully documented;\n* history or current evidence of cancer of any aetiology and location besides skin cancer in situ successfully treated before the enrolment;\n* severe patient's conditions which may lead to misinterpretation of data, or in case of patient's enrolment may put him at risk of exacerbation of co-morbid conditions, or in cases when on discretion of the investigator patient's condition would not allow him to complete the course of the observation. These conditions include, but not limited to: heart failure (class III-IV by NYHA), uncontrolled hypertension, severe neurological disorders, decompensated liver cirrhosis (Child-Pugh B or C), severe depression or other psychological disorders;\n* the patient may stop his participation in the study at any time by informing the site personal about his\u002Fher decision to withdraw the consent.","80 Years",{"count":189,"type":21},150,[24],"This study is aimed to investigate the role of long-term diet adherence on manifestations of gastroesophageal reflux disease",[27,193,194,195,196,197],"GERD","Gastroesophageal Erosion","Erosive Esophagitis","Non-erosive Reflux Disease","Non-Erosive Gastro-Esophageal Reflux Disease",[193,199,200,201,202,203,204],"NERD","erosive esophagitis","diet","food","adherence","influence","2025-08-01",{"date":207,"type":35},"2025-08-03",{"date":209,"type":35},"2020-01-31",{"date":147,"type":21},{"name":212,"class":42},"Federal State Budgetary Scientific Institution \"Federal Research Centre of Nutrition, Biotechnology",{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":22,"phases":222,"briefSummary":224,"conditions":225,"keywords":226,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":126},"100592278","phase-4-clinical-trial-for-the-comparative-evaluation-of-acid-suppression-and-symptom-management-of-gastroesophageal-reflux-disease-with-the-administration-of-tegoprazan-or-pantoprazole-100592278","NCT06991348","Clinical Trial for the Comparative Evaluation of Acid Suppression and Symptom Management of Gastroesophageal Reflux Disease With the Administration of Tegoprazan or Pantoprazole","Multicenter, Active-controlled, Randomized, Double-blind, Clinical Trial for the Comparative Evaluation of Acid Suppression and Symptom Management of Gastroesophageal Reflux Disease With the Administration of Tegoprazan or Pantoprazole: TOP-GERD","TOP-GERD","Inclusion Criteria:\n\n* With endoscopic diagnosis of GERD or NERD (endoscopy ≤ 15 days old)\n* With positive impedance pHmetry results (pHmetry ≤ 15 days old)\n* With recurrent symptoms of heartburn and regurgitation for a previous period ≥ 3 months old\n\nExclusion Criteria:\n\n* With known hypersensitivity to tegoprazan, pantoprazole, or any of the components of each formulation\n* Subjects with concomitant administration of atazanavir, nelfinavir or rilpivirine\n* Nephropathic and\u002For hepatopathic subjects (including non-alcoholic hepatitis)\n* Subjects with upper gastrointestinal tract bleeding\n* Subjects with gastric and\u002For duodenal ulcer 2 months prior to screening\n* Subjects with a history of esophageal or gastric surgery",{"count":54,"type":21},[223],"PHASE4","The objective of this clinical trial is to compare which of the two drugs best resolves symptoms in patients diagnosed with erosive and non-erosive gastroesophageal reflux disease, adult males and females. The main question is What is the proportion of patients with resolution of the main symptoms of gastroesophageal reflux disease at four weeks of treatment with pantoprazole vs tegoprazan.",[27],[193,227,228,229,230],"pantoprazole","tegoprazan","P-CAB","PPI","2025-07-18",{"date":233,"type":35},"2025-07-23",{"date":235,"type":35},"2024-07-30",{"date":237,"type":21},"2025-11-30",{"name":239,"class":240},"Carnot Laboratories","INDUSTRY",{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":249,"targetDuration":4,"studyType":22,"phases":251,"briefSummary":252,"conditions":253,"keywords":254,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":261,"leadSponsor":263,"locationsCount":102},"100596733","phase-3-mandibular-advancement-devices-for-reflux-in-obstructive-sleep-apnea-100596733","NCT07049315","Mandibular Advancement Devices for Reflux in Obstructive Sleep Apnea","Effect of Oral Mandibular Advancement Devices on Nocturnal Gastroesophageal Reflux in Adults With Obstructive Sleep Apnea: A Randomized Controlled Trial","MAD-ROSA","Inclusion Criteria:\n\n* Adults aged 18 to 65 years\n* Clinical diagnosis of obstructive sleep apnea (OSA) confirmed by polysomnography type I\n* Presence of nocturnal gastroesophageal reflux symptoms\n* Not currently using CPAP therapy\n* Dentate individuals able to wear oral devices\n* Able and willing to comply with the study protocol\n* Provided written informed consent\n\nExclusion Criteria:\n\n* Severe OSA (Apnea-Hypopnea Index \\> 30)\n* Current or recent use of proton pump inhibitors or other anti-reflux medications\n* Neurological or neuromuscular disorders\n* Use of removable dental prostheses (partial or total)\n* Prior surgeries for apnea or reflux\n* Known allergy or intolerance to dental acrylic materials\n* Inability to attend follow-up visits or complete questionnaires",{"count":250,"type":21},40,[84],"The purpose of this randomized clinical trial is to learn if a mandibular advancement device (a type of oral appliance) can help reduce nighttime acid reflux in adults with obstructive sleep apnea. The study also aims to understand whether this device can improve sleep quality and quality of life.\n\nThe main questions the study aims to answer are:\n\n* Does using a mandibular advancement device reduce the number and intensity of nighttime reflux episodes?\n* Does the device improve sleep and daily well-being in people with sleep apnea and reflux?\n\nResearchers will compare two types of oral appliances:\n\n* A mandibular advancement device, which moves the lower jaw forward during sleep\n* A lower jaw oral device without advancement, which also aims to help people with sleep apnea but does not reposition the jaw\n\nParticipants will:\n\nWear the assigned oral device every night for 6 months Visit the clinic for check-ups and adjustments Complete short questionnaires about reflux symptoms, sleep quality, swallowing, diet, and quality of life Have saliva pH measured and X-rays taken before and after using the device This study hopes to find out whether oral devices can be a good option for people who do not tolerate CPAP therapy.",[27],[255,256],"Gastroesophageal reflux","Sleep Apnea, Obstructive","2025-07-02",{"date":259,"type":35},"2025-07-08",{"date":205,"type":21},{"date":262,"type":21},"2026-12-01",{"name":264,"class":42},"Tuiuti University of Paraná",{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":230,"eligibilityCriteria":271,"healthyVolunteers":11,"sex":16,"minAge":272,"maxAge":273,"enrollmentInfo":274,"targetDuration":4,"studyType":276,"phases":4,"briefSummary":277,"conditions":278,"keywords":281,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":102},"100595759","intestinal-microbiota-after-ppi-treatment-100595759","NCT07036627","Intestinal Microbiota After PPI Treatment","Evaluation of the Intestinal Microbiota in Pediatric Patients Treated With Proton Pump Inhibitors: A Prospective Longitudinal Study","Inclusion Criteria:\n\n* Male or female children and adolescents aged between 6 months and 17 years at the time of enrollment.\n* Clinical indication for proton pump inhibitor therapy, including but not limited to gastroesophageal reflux disease, esophagitis, or functional dyspepsia.\n* Willingness and ability of the child and their caregivers to comply with all study procedures, including collection of fecal samples at scheduled time points.\n* Written informed consent obtained from a parent or legal guardian; assent obtained from the child, when age-appropriate, in accordance with local regulations and ethical standards.\n\nExclusion Criteria:\n\n* Use of systemic antibiotics, antifungals, or probiotics within 30 days prior to the start of the study or during the observation period.\n* Incomplete or improperly handled stool sample collection, or failure to adhere to protocol-defined sampling windows.\n* Known diagnosis of primary immunodeficiency, inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis), or celiac disease.\n* Any condition that, in the opinion of the investigator, may interfere with the integrity of the study or pose additional risks to the participant.","6 Months","17 Years",{"count":275,"type":21},100,"OBSERVATIONAL","This clinical study aims to investigate the effects of short-term treatment with proton pump inhibitors (PPIs) on the gut microbiota of pediatric patients. PPIs are among the most frequently prescribed medications in children and adolescents for the management of acid-related disorders, such as gastroesophageal reflux disease (GERD). However, emerging evidence suggests that these medications may have unintended consequences on the delicate ecosystem of beneficial microorganisms residing in the human gastrointestinal tract.\n\nThe intestinal microbiota plays a pivotal role in modulating immune responses, supporting nutrient metabolism, and maintaining the integrity of the gut barrier. Disruption of this microbial balance-known as dysbiosis-has been associated with several health conditions, including infections, allergies, obesity, and chronic inflammation. In adults, long-term PPI use has been linked to microbiota alterations, but data in the pediatric population remain limited and inconclusive.\n\nTo address this gap, our prospective longitudinal study will recruit pediatric patients prescribed PPI therapy for clinical indications. Stool samples will be collected at four time points: prior to PPI administration, during treatment, and at two follow-up stages post-cessation. Using 16S rRNA gene sequencing, we will profile changes in microbial diversity and abundance over time.\n\nThe results will offer insight into whether short-term PPI exposure in children leads to significant, lasting changes in gut microbiota composition or diversity. Such information may ultimately inform prescribing practices, support personalized therapeutic strategies, and help mitigate potential risks associated with microbiota disruption during childhood-a critical period for microbial and immune system development.",[279,280,27],"Proton Pump Inhibitors","Human Gastrointestinal Tract",[230,193,282,283],"microbiota","gastroesophageal reflux","2025-06-25",{"date":286,"type":35},"2025-06-29",{"date":288,"type":21},"2025-07-06",{"date":290,"type":21},"2027-02-01",{"name":292,"class":42},"University of Bari",{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":301,"targetDuration":4,"studyType":22,"phases":302,"briefSummary":303,"conditions":304,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":314},"100593284","a-post-market-registry-to-assess-safety-and-performance-of-refluxstop-in-the-treatment-of-gerd-in-general-hospital-practice-100593284","NCT07004439","A Post-market Registry to Assess Safety and Performance of RefluxStop™ in the Treatment of GERD in General Hospital Practice","A Post-market Registry Study Based on Standard Clinical Care to Assess Safety and Performance of RefluxStop™ in the Treatment of Gastroesophageal Reflux Disease (GERD) in General Hospital Practice","RESTORE500","Inclusion Criteria:\n\n1. Willing and able to provide informed consent and to participate in the registry study;\n2. Age ≥ 18 years or according to local legal age of adulthood at the location of the test site if older;\n3. Documented GERD present for ≥ 6 months. Typical symptoms are defined as heartburn;\n4. 24-hour pH or impedance pH monitoring proven GERD with pH measurement, off PPI therapy for at least 7 days prior to testing. (Total distal esophageal pH must be \\\u003C 4 for ≥ 4.5% of total time during a 24-hour monitoring) and\u002For total reflux episodes \\>55 or weekly acid \\>26 for \\> 5 seconds, all measured 5 cm above LES);\n5. Suitable to undergo general anaesthesia and is a suitable laparoscopic surgery candidate as determined by the investigator.\n\nExclusion Criteria:\n\n1. Hiatal Hernia larger than 8 cm;\n2. Known presence of delayed gastric emptying, if no other cause for acid reflux could be diagnosed. Patients with substantially weak peristalsis (manometry DCI value 100-200) in esophagus measured during manometry would continue the simplified contrast swallow x-ray to perform a simplified two-hour gastric emptying contrast swallow\n3. History of bariatric surgery wherein the stomach fundus has been extirpated;\n4. Female subjects who are pregnant;\n5. Known sensitivity or allergies to silicone materials;\n6. Intraoperative findings determined by the investigator that may result in unfavorable conduct of the registry procedure (as outlined in the IFU);\n7. Subjects that are unable to comply with the registry requirements (for example due to major psychiatric disorder or are considered otherwise unsuitable for participation in the clinical investigation according to the investigator's judgement).",{"count":20,"type":21},[24],"A post-market retrospective and prospective, open label, multicenter, single-arm registry study using standard clinical procedures to record available and\u002For new data to evaluate the safety and performance of RefluxStop™ for the treatment of subjects suffering from GERD.\n\nFollowing surgery, patients will have follow-ups visits at 3 and 6 months and annually up to 7 years.",[27],"2025-05-27",{"date":307,"type":35},"2025-06-04",{"date":309,"type":21},"2025-09-15",{"date":311,"type":21},"2035-08-01",{"name":313,"class":240},"Implantica CE Reflux Ltd.",5,{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":321,"eligibilityCriteria":322,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":323,"enrollmentInfo":324,"targetDuration":4,"studyType":22,"phases":326,"briefSummary":327,"conditions":328,"keywords":329,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":102},"100542865","anti-reflux-mucosal-valvuloplasty-versus-ppis-for-gerd-treatment-100542865","NCT06348420","Anti-reflux Mucosal Valvuloplasty Versus PPIs for GERD Treatment","Anti-reflux Mucosal Valvuloplasty Versus Proton Pump Inhibitors for the Treatment of Patients With Gastroesophageal Reflux Disease in a Tertiary Healthcare Center in China: Study Protocol for a Randomized Controlled Trial","ARMV","Inclusion Criteria:\n\n* 18-60 years of age;\n* Hiatal hernia ≤ 2 cm;\n* Sliding hernia ≤ 2 cm;\n* Recurrence of GERD symptoms after cessation of PPIs;\n* On daily PPI for ≥1 year or twice daily PPI for at least 8 weeks;\n* Esophagitis (Los Angeles Classification) Grade B, C, or D;\n* Hill's flap valve grade ≤ III;\n* Observation of distal esophageal pH \\\u003C 4 on at least 1-2 days within a 7-day period, with a percentage exceeding 5.3%;\n* Normal or near-normal esophageal motility;\n* Lower esophageal sphincter pressure (LESP) ranging between 5-15 mmHg;\n* DeMeester score ≥ 14.7 or total reflux episodes exceeding 73;\n* Completion of a signed informed consent form.\n\nExclusion Criteria:\n\n* BMI \\> 35 kg\u002Fm2;\n* ASA \\> II;\n* Barrett's esophagus;\n* Hiatal hernia \\> 2 cm;\n* Esophagitis (Los Angeles Classification) Grade A or No esophagitis；\n* Hill's flap valve grade \\> III；\n* Peptic ulcer disease;\n* Primary esophageal motility disorders such as achalasia;\n* Severe gastroparesis;\n* History of previous esophageal or gastric surgery, including ARMS or ARMA;\n* Uncontrolled systemic diseases;\n* Gastric outlet obstruction;\n* Pregnancy or planning to become pregnant.","60 Years",{"count":325,"type":21},74,[24],"The study objective is to evaluate the relative merits, safety and effectiveness of Anti-reflux mucosal valvuloplasty (ARMV) in GERD patients currently treated with daily Proton Pump Inhibitors (PPIs).",[27],[330,331,332,333],"Endoscopic anti-reflux","Proton pump inhibitor","Randomized controlled trial","Gastroesophageal reflux disease","2024-11-14",{"date":336,"type":35},"2024-11-18",{"date":338,"type":35},"2024-09-10",{"date":340,"type":21},"2028-12-30",{"name":342,"class":42},"Qilu Hospital of Shandong University",{"id":344,"slug":345,"hasResults":11,"nctId":346,"briefTitle":347,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":133,"enrollmentInfo":350,"targetDuration":4,"studyType":276,"phases":4,"briefSummary":352,"conditions":353,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":358,"leadSponsor":359,"locationsCount":4},"100554826","gastroesophageal-reflux-disease-diagnostic-trial-100554826","NCT06504134","Gastroesophageal Reflux Disease Diagnostic Trial","GERDT","Inclusion Criteria:\n\n1. ≥18 years and ≤85 years, male or female;\n2. A visit was made for symptoms such as persistent reflux, heartburn, bloating, early satiety, and belching;\n3. Patients volunteered to participate in the clinical trial, signed an informed consent form, and were able to cooperate with clinical follow-up.\n\nExclusion Criteria:\n\n1. History of esophageal surgery;\n2. Presence of dysphagia, esophagogastric fundal varices, or esophageal stenosis;\n3. Presence of coagulation disorders or taking anticoagulant or antiplatelet drugs;\n4. Those with a life expectancy of less than 5 years;\n5. Persons with mental anomalies who are incapable of behavioral autonomy;\n6. Other conditions that, in the judgment of the physician, preclude participation in the trial.",{"count":351,"type":21},1000,"Gastroesophageal reflux disease (GERD) is a very common condition in clinical practice. In China, GERD affects nearly 150 million patients, whose quality of life are seriously impacted. Currently, the diagnosis of GERD primarily depends on the results of 24h reflux monitoring. However, such examination is under a quite low acceptability. As a result, a large number of patients were not diagnosed timely and accurately, and serious social problems are induced, such as drug abuse of proton pump inhibitor. Our team has previously developed a novel device for esophageal cell enrichment and established an internationally pioneering method of cytological screening for esophageal cancer based on cutting-edge deep learning technology. This project aims to develop multiple deep learning algorithms and establish an innovative method for diagnosis of GRED, using the novel esophageal cell enrichment technology. The research includes: 1) constructing deep learning algorithms for automatic esophageal inflammatory cells recognition and classification; 2) mining and extracting the key features of esophageal squamous cells and inflammatory cells under physician-AI interaction; 3) establishing a prediction model for GERD by integrating digital features of squamous cells and inflammatory cells and building a cloud-based automatic diagnosis system; 4) investigating the immuno-infiltration atlas of GERD and its diagnostic value based on the enriched inflammatory cells. The ultimate goal is to solve current clinical problems and realize rapid, convenient, and accurate diagnosis of GERD.",[27],"2024-07-14",{"date":356,"type":35},"2024-07-16",{"date":235,"type":21},{"date":147,"type":21},{"name":360,"class":42},"Changhai Hospital",{"id":362,"slug":363,"hasResults":11,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":368,"targetDuration":4,"studyType":22,"phases":370,"briefSummary":371,"conditions":372,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":4},"100553107","zuojin-wan-combined-with-woonosan-fumarate-for-the-treatment-of-grd-combined-with-depression-100553107","NCT06481787","Zuojin Wan Combined With Woonosan Fumarate for the Treatment of GRD Combined With Depression","A Single-centre Randomised Controlled Study of 8-week Zuojinwan in Combination With Volnoxan Fumarate for the Treatment of Gastro-oesophageal Reflux Disease Combined With Depression","Inclusion Criteria:\n\n1. Aged between 18 and 65 years;\n2. Fulfilment of western medical diagnostic criteria for GERD;\n3. Meet the diagnostic criteria for mild depression;\n4. Comply with the diagnostic criteria of Liver and Stomach Depression-Heat syndrome in Chinese medicine;\n5. A score of 7-17 on the 17-item Hamilton Depression Scale (HAMD-17) (7-17 being mild depression);\n6. Good compliance and autonomous behaviour;\n7. No medications that may have an effect on the study, such as acid-suppressing agonists, were taken within 2 weeks prior to enrolment;\n\nExclusion Criteria:\n\n1. HP positive patients;\n2. Other organic diseases of the digestive system, such as peptic ulcer, peptic tumour, peptic haemorrhage, liver, gallbladder and pancreas disease, intestinal obstruction and inflammatory bowel disease;\n3. Systemic diseases affecting the dynamics of the digestive tract, such as diabetes mellitus, chronic renal insufficiency, connective tissue diseases, neurological lesions, etc;\n4. Pathological diagnosis of the esophageal mucosa suggestive of moderate-to-severe heterogeneous hyperplasia;\n5. Previous surgery resulting in a decrease in gastric acid or a history of oesophageal or gastric surgery;\n6. Varicose veins in the esophagus or fundus of the stomach;\n7. Persons with severe primary heart, brain, liver, lung, kidney, blood or serious disease affecting their survival;\n8. Those with depression, suicidal tendencies and mental disorders who cannot cooperate;\n9. Pregnant or breastfeeding women, or patients who have a plan to have children in the near future;\n10. Taking drugs that have an effect on the results of this study within 2 weeks before participating in this study;\n11. Allergy or adverse reaction to the study drug.",{"count":369,"type":21},300,[24],"To evaluate the improvement of symptoms in patients with gastroesophageal reflux disease combined with depression (hepatic and gastric depression-heat type) by Zuojin Wan combined with vornodine fumarate regimen as a control, and to compare the adherence to the medication and the adverse reactions of the patients between the two groups.",[27,373],"Depression","2024-06-28",{"date":376,"type":35},"2024-07-01",{"date":378,"type":21},"2024-06-30",{"date":380,"type":21},"2026-06-30",{"name":382,"class":42},"Nanjing First Hospital, Nanjing Medical University",{"id":384,"slug":385,"hasResults":11,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":390,"enrollmentInfo":391,"targetDuration":4,"studyType":22,"phases":393,"briefSummary":394,"conditions":395,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":4},"100524236","anti-reflux-mucosal-ablation-therapy-randomized-sham-control-trial-for-gastroesophageal-reflux-disease-100524236","NCT06106100","Anti-reflux Mucosal Ablation Therapy Randomized Sham Control Trial for Gastroesophageal Reflux Disease","Efficacy and Safety of Endoscopic Anti-reflux Mucosal Ablation Therapy for Gastroesophageal Reflux Disease: a Single Blind Randomized Sham Controlled Trial","Inclusion Criteria:\n\n* Adults aged over 18 years old\n* History of GERD for over 6 months, who had received PPIs for over 6 months but still had symptoms of typical GERD symptoms (GERD-HRQL score of \\>8, acid reflux sensation or heartburn), and\u002For other symptoms as lump throat, night cough, acid related chest tightness (without other possible explanation of these symptoms)\n* Acid exposure time \\> 6%\n* DeMeester score ≥ 14.72\n\nExclusion Criteria:\n\n* Pregnancy\n* BMI\\>=35\n* Hiatal hernia \\> 2cm or Flap Valve Hill grade III\u002FIV\n* GERD LA grade C\u002FD or esophageal ulcer\n* Abnormal anatomy of esophagus (esophagectomy, stricture, diverticulum)\n* Barrett's esophagus with dysplasia\n* Esophageal motility disorders\n* History of gastroparesis\n* Cirrhosis\n* Esophageal and gastric varices\n* Previous gastric surgery and anti-reflux procedures\n* History of scleroderma or dermatomyositis\n* Coagulation disorders (Bleeding tendency and coagulopathy)\n* History of oncological disease (not active within 2 years)","75 Years",{"count":392,"type":21},68,[24],"The goal of this randomized clinical trial is to investigate the efficacy and safety of antireflux mucosal ablation (ARMA) for patients with refractory gastroesophageal reflux disease (GERD). The trial aim to evaluate :\n\n* Efficacy of ARMA comparing with medical treatment alone (proton pump inhibitor (PPI)), using GERD-Health Related Quality of Life Questionnaire (GERD- HRQL questionnaire), improvement of acid exposure time and DeMeester score\n* Safety and complications of ARMA Participants will be randomly divided into 2 groups. The intervention group will be undergone ARMA, and the control group will be undergone sham endoscopic treatment.\n\nThe primary endpoint will be symptoms relief (GERD-HRQL decreases \\> 50%). The secondary endpoint will be dosage adjustment of PPI, complications, improvement of acid exposure time and DeMeester score.",[27],"2024-02-21",{"date":398,"type":35},"2024-02-23",{"date":400,"type":21},"2024-03",{"date":402,"type":21},"2027-10",{"name":404,"class":42},"Far Eastern Memorial Hospital",{"id":406,"slug":407,"hasResults":11,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":412,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":413,"targetDuration":4,"studyType":276,"phases":4,"briefSummary":415,"conditions":416,"keywords":419,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":102},"100100786","progression-of-gastroesophageal-reflux-disease-and-barretts-esophagus-and-the-creation-of-a-barretts-registry-100100786","NCT00574327","Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry","A Prospective Study To Define The Role Of Various Factors In Development And Progression Of Gastroesophageal Reflux Disease (GERD) And Barrett's Esophagus And The Creation Of A Registry.","All patients must be eligible for care that the Kansas City VA Hospital where this study was approved for enrollment.\n\nInclusion Criteria:\n\n* Kansas City VA Patients with confirmed BE with and without dysplasia and patients with reflux disease (patients\u002Fcases); patients with other indicators for endoscopy such as anemia, weight loss, diarrhea, but without GERD and PE (controls).\n\nExclusion Criteria:\n\n* Patients with uncontrolled significant comorbidities such as cardiovascular, pulmonary, renal, hepatic or metabolic diseases.\n* Presence of anticoagulation that would increase risk from biopsies\n* Patients unable to provide history\n* Patients with dyspepsia",true,{"count":414,"type":21},3000,"The purpose of this study is to determine or evaluate the risk factors such as smoking, family history etc. that cause esophageal cancer and to determine the genetic changes that lead to esophageal cancer. The investigators hypothesis is that systematic collection of data on the natural history of GERD and BE patients and risk factors for development of BE in patients with chronic GERD and progression of BE to dysplasia and adenocarcinoma will provide useful information to develop a decision model for risk stratification and risk reduction strategies in these patients.\n\nAs of March 17, 2011, 585 patients have consented at the Kansas City VA Medical Center.",[417,27,418],"Barrett's Esophagus","Esophageal Adenocarcinoma",[420,421,417],"Role","Registry","2023-03-15",{"date":424,"type":35},"2023-03-16",{"date":426,"type":4},"2006-01",{"date":428,"type":21},"2029-01",{"name":430,"class":42},"Midwest Biomedical Research Foundation"]